These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 512353)

  • 41. Failed rubella immunization in adults: association with immunologic and virological abnormalities.
    Tingle AJ; Chantler JK; Kettyls GD; Larke RP; Schulzer M
    J Infect Dis; 1985 Feb; 151(2):330-6. PubMed ID: 3968452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence of antibody titers after vaccination with rubella virus vaccine ("Cendehill" strain).
    Peetermans J; du Pan RM; Huygelen C
    Dev Biol Stand; 1979; 43():361-5. PubMed ID: 520683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
    Hum Immunol; 2004 Dec; 65(12):1506-15. PubMed ID: 15603879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children.
    Naficy K; Nategh R; Ahangary S; Mohsenin H
    Am J Dis Child; 1970 Dec; 120(6):520-3. PubMed ID: 5481902
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical trial of the Cendehill strain of live, attenuated rubella virus vaccine].
    Page W; Fattorini A
    Minerva Med; 1970 Apr; 61(30 Suppl):1601-12. PubMed ID: 5439726
    [No Abstract]   [Full Text] [Related]  

  • 46. In vivo expression of rubella antigens on human leucocytes: detection by flow cytometry.
    O'Shea S; Mutton D; Best JM
    J Med Virol; 1988 Jul; 25(3):297-307. PubMed ID: 3049939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Joint symptoms following an area-wide rubella immunization campaign--report of a survey.
    Wallace RB; Libert P; Ibrahim M; Isacson P
    Am J Public Health; 1972 May; 62(5):658-61. PubMed ID: 5024291
    [No Abstract]   [Full Text] [Related]  

  • 48. Persistence of antibody induced by rubella vaccine (Wistar RA 27/3 strain) after six years.
    Hillary IB; Freestone DS
    J Hyg (Lond); 1975 Dec; 75(3):407-11. PubMed ID: 1059708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team.
    Ray P; Black S; Shinefield H; Dillon A; Schwalbe J; Holmes S; Hadler S; Chen R; Cochi S; Wassilak S
    JAMA; 1997 Aug; 278(7):551-6. PubMed ID: 9268275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Rubella vaccination: antibody persistence for 14-17 years and immune status of women without and with a history of vaccination].
    Enders G; Nickerl U
    Immun Infekt; 1988 Apr; 16(2):58-64. PubMed ID: 3391631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Trials of vaccination against rubella with the Cendehill C-51 strain of live and attenuated virus].
    Fara GM; Galli MG; Nodari R; Saccani CF; Marangoni L; Bozzetti A; Tarantino F
    Minerva Med; 1970 Apr; 61(30 Suppl):1574-7. PubMed ID: 5439721
    [No Abstract]   [Full Text] [Related]  

  • 52. Further studies of an attenuated rubella strain grown in WI-38 cells.
    Plotkin SA; Farquhar JD; Katz M; Hertz C
    Am J Epidemiol; 1969 Feb; 89(2):232-8. PubMed ID: 5765961
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibody response to rubella ribonucleoprotein component after natural infection and after immunization.
    Ho-Terry L; Cohen A
    J Med Microbiol; 1981 Feb; 14(1):141-5. PubMed ID: 7463463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Rubella immunization with HPV77DE5 and RA 27/3 vaccines of 11 to 16-year-old girls: studies of antibody formation and antibody resistance after 4 and 8 years].
    Gitmans U; Enders G; Glück H; Harm B; Lindemann L
    Immun Infekt; 1983 May; 11(3):79-90. PubMed ID: 6676174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of immunoglobulin M-antibodies after rubella immunization with RA27/3 attenuated live vaccine in teen-agers: remaining problems.
    Braito A; Fanti O; Rossolini GM; Cellesi C
    Boll Ist Sieroter Milan; 1991-1992; 70(1-2):443-8. PubMed ID: 1670047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination.
    Ovsyannikova IG; Jacobson RM; Ryan JE; Dhiman N; Vierkant RA; Poland GA
    Clin Vaccine Immunol; 2007 Feb; 14(2):115-22. PubMed ID: 17215337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rubella vaccine trial in children.
    Hillary IB; Meenan PN; Griffith AH; Draper CC; Laurence GD
    Br Med J; 1969 May; 2(5656):531-2. PubMed ID: 5769885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trial of high-titre human rubella immunoglobulin.
    Urquhart GE; Crawford RJ; Wallace J
    Br Med J; 1978 Nov; 2(6148):1331-2. PubMed ID: 363233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of antibody 10 years after vaccination with Wistar RA27/3 strain live attenuated rubella vaccine.
    Hillary IB; Griffith AH
    Br Med J; 1980 Jun; 280(6231):1580-1. PubMed ID: 7427177
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunity and anti-rubella vaccination].
    Delville JP; Tellini-Emma M
    Arch Belg Med Soc; 1970 May; 28(5):321-30. PubMed ID: 5494764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.